Olga V Ponomarova

  • Citations Per Year
Learn More
BACKGROUND Bavituximab is a phosphatidylserine-targeting antibody with a selective tumor, vascular-directed immune response. In this phase II trial the efficacy and safety of bavituximab combined with docetaxel for previously treated, advanced nonsquamous non-small-cell lung cancer were evaluated. PATIENTS AND METHODS Patients were randomized 1:1:1 to(More)
The principles of therapeutic tactics in patients with indolent non-Hodgkin’s B-cell lymphomas are presented. The results of clinical trials that studied different regimens (with usable chemotherapy, target, radiation therapy, hematopoietic stem cells transplantation) of treatment of patients with this disease are summarized. Data on morphological,(More)
  • 1